Device for cancer tissue treatment

FIELD: medical equipment.

SUBSTANCE: invention concerns medical equipment and can be applied in cancer tissue treatment in various organs of biological objects. Device includes semiconductor laser diode, clock generator, semitransparent mirror, comparator, first, second and third direct current amplifiers, differentiating amplifier, discriminating amplifier, first and second photo receivers, delay line, analog to digital converter, programmed permanent memory, first and second binary code comparators, first and second control systems of secondary power sources, first and second secondary power sources and light panel/indicator. Biological object is positioned in line between semiconductor laser, semitransparent mirror and second photo receiver.

EFFECT: extended range of technical devices for laser cancer therapy.

4 dwg

 

The invention relates to medicine and can be used for the treatment of cancer tissues of different biological systems.

Modern medicine in the treatment of cancer seeks to destroy cancer cells/tissues. To kill cancer cells using surgery, radiation therapy, chemotherapy, and treatment of selective action (lasers, a betatron, a variety of particle accelerators and the like).

Known devices that implement known methods of therapy of cancerous tissue selective action, differ only in specific types of lasers and technical performance of systems focusing lenses, while maintaining the same structural scheme of the device as a whole. Therefore, as a prototype, consider the following device [N.M. Emanuel, R.E. Kavetsky, Tarusov B.N., The OfP H.E. Biophysics of cancer. - Kiev: Nauk. Dumka, 1976. - 296 S.].

A device for implementing the known method of treating cancerous tissue (see figure 1) consists of a source of supply (PS), generation and selection of modes of operation of the laser (SF), direct active emitter laser (L) and systems focusing lenses (SFL), which are connected in series.

The device operates as follows. When the power supply is the operator using SF selects the desired mode of operation of the laser, the wavelength of which definition is Lena active structure, for example, pulsed, with adjustable parameters (pulse duration, the steepness of its front and rear front and so on), or continuous operation modes of the optical signal active structure, i.e. the laser. The output optical flow statement can also be changed by control of the SFL. For example, the focusing optical flow on a small area, you can increase its density/exposure, and Vice versa, rastaquouere to reduce its density/exposure. In practical circuits the source of the light flux are lasers based on Rubin (λ=694,3 nm) and neodymium (λ=1060 nm), it is possible to use semiconductor laser diodes.

A disadvantage of the known device is that it cannot directly be used to implement the claimed method of treatment of cancer tissues. The operator cannot provide the antiphase mode lasing wavelength of the laser in relation to the fluctuations of the cancer cells. The initial phase of the oscillation laser is always random. Density /power flow exposure is selected by the operator and, as a rule, far exceeds the required power for operation. The operator, achieving a positive result, deliberately overstates the power flow exposure to compensate for the different accident in the course of treatment.

The closest to request aemono device is another known device [US 5634922 (Hamamatsu Photonics K.K.) Jun. 3, 1997]. Figure 2 shows a diagram of an endoscopic system that implements the control, diagnostics and treatment of malignant tissues. Endoscopic system with the help of an endoscope 2 lets you visually through optics to find in the internal organs, areas of suspected malignant tissue 1 by illumination from the white light source 9 through the optical fiber 5. Qualitative visual inspection of malignant plot tissues 1 through reflected from the surface of the signal through the optical fiber 6 with a color video camera 10 is logged on the television monitor 16. A set of data elements comprises controlling circuit 3 total endoscopic system.

Optical diagnostics and treatment are provided by the scheme 4 total endoscopic system. It includes a special laser generator 17, which allows the components 11 and 12 respectively generate two working wavelength: for diagnostic 405 nm and treatment - 630 nm. Depending on the mode switch 14, the signal from the generator 17 channels diagnostics 11 or canal treatment 12. The output of the generating circuit of the optical signal of the laser is delivered through the optical fiber 7 into the working area of the tissue 1.

For implementing diagnostics of bioobject pre intravenous injection specifications is determined as being a contrast substance, for example, substance HpD (symbol contrast agent according to the materials of the patent application prototype). When the inclination of the laser beam of 405 nm to diagnose tissue fluorescence occurs with two peaks 630 and 690 nm. This signal through the optical fiber 8 is supplied to the spectroscope 13, the output of which is implemented range 15. This spectral signal 15 by means of a highly sensitive camera 18 is converted into a video signal and further processed by the analyzer 19 to obtain graphic images of fluorescence on the television monitor 20 (actually television monitors 16 and 20 function as the scoreboard indicator).

The presence of fluorescent patterns with two peaks is a classification characteristic of malignant tissue and the basis for the switching device from the diagnostic mode on the mode of treatment. The switch 14 to the light guide 7 in the area cancer tumor, which is strictly defined and fixed at the preliminary stage of diagnosis, directs the laser beam 630 nm and physically destroys the hearth. The changing composition of the contrast agent imposes restrictions on the wavelength of the channel 12. This requires the creation of laser generator 17 with special opportunities for the restructuring of the working wavelength.

As follows from the description of the device for the diagnosis and treatment of cancer tkane the Central node of the endoscopic system is the design of the laser generator 17, having the opportunity to rebuild a working wavelength. Figure 3 presents a diagram of the device of the laser generator 17.

A basis of the laser generator is a solid-state laser generator 1 (semiconductor laser), the output of which there is selective element 2, for example a movable optical prism. It allows the laser beam with the desired wavelength within a wide range of wavelengths to be selectively directed to a harmonic generator 3, the signal of which is fed to an optical parametric generator 4. It consists of a collimator lens 5, the two mirrors 6 and 8, between which is a nonlinear optical crystal 7 type BBO or LBO (see the description of the prototype). Control of non-linear optical crystal is carried out by the control unit 10 by means of a special rotating element 9, which is achieved by a specified angle of incidence of the laser beam on the nonlinear element 7. The angle is determined by the composition of the contrast agent and is related to the laser wavelength. Therefore, the control unit 10 performs synchronous control and directly by the laser 1. In the end, the output of the parametric generator 4 generates two signals required wavelengths. To separate the signal into two optical channel is used dichroic filter 12. Direct the laser beam through obizatelno lens 14 is fed to the input optical fiber 16 and is used as a therapeutic. The other laser beam is reflected from the deflector and is supplied to the second harmonic generator 13, where a diagnostic laser beam. He also through the collective lens 15 is fed to the input optical fiber 17 and is used as a diagnostic.

A disadvantage of the known device is dependent on the stage of diagnosis of the type of contrast agent, which is administered by intravenous injection. This effect of treatment depends on the dose of irradiation with laser beam precision guidance of a cancerous lesion. Keep in mind the fact that the shape of the lesion can be varied, and the presence of metastasis requires a special algorithm, the sequence of their destruction.

The proposed device for the treatment of cancerous tissues Biosystems is a set of fixtures and devices, and it is based on a semiconductor laser diode, in addition to which it also contains a translucent mirror, two of the photodetector comparing device, a clock generator, three DC amplifier, differential amplifier, the amplifier-discriminator, delay, analog-to-digital Converter with display-indicator, programmable permanent memory device, the two devices compare binary, two schemes control secondary power sources and DV is the secondary power source.

Common to the selected applicant prototype and the proposed device is the presence of:

semiconductor laser diode;

- semi-transparent mirrors;

- scoreboard indicator.

Distinctive features of the prototype signs of the following:

the oscillator;

- comparing device;

three DC amplifier;

- differentiating amplifier;

amplifier-discriminator;

two of the photodetector;

the delay line;

- analog-to-digital Converter;

- programmable permanent memory;

two devices compare binary;

two control circuit secondary power sources;

two secondary power source, and the connections between these devices are described in the claims. In particular, it is essential to the location of the object being diagnosed on the way of working of the light flux between the semiconductor laser diode, a semi-transparent mirror and the second photodetector. It provides information about the ratio of the initial phases of the oscillations of the radiation source and the actual cancerous cells. The chain formed by the first photodetector and the second DC amplifier comparing device and the first DC amplifier, creates a channel negative feedback, both the providing stabilization of the mode of generation of coherent light flux capacity. The clock generator provides the timing of the initial phase of the coherent light flux with the initial phase of oscillations of the cancer cell. For this purpose, the channel automatically control the initial phase of the radiation source, which consists of the second sensor, the third DC amplifier, differential amplifier, delay line and amplifier-discriminator. To monitor and control the operating wavelength of laser equipment is designed circuit based on the analog-to-digital Converter with display-indicator, programmable permanent memory device, the two devices compare binary, two control circuits secondary power sources and two secondary power sources. It should be noted that the first comparator binary processes the signals of the high-order bits programmable permanent memory device and the second signals respectively low. This allows more precise control of the operating wavelength of the laser setup.

The technical result of the invention consists in expanding Arsenal of technical tools when implementing laser oncotherapy.

The proposed device for the treatment of cancerous tissues is shown in Figure 4.

It contains the oscillator (the G) 1, the output of which is connected to the first input of the first DC amplifier (UT) 2. Output UT 2 is connected to the first input of a semiconductor laser diode (within) 3 and the first input of the comparing unit (SU) 4. Exit SU 4 is connected with the second input UT 2. The output optical flow within partially reflected from the semitransparent mirror 5 and enters the first photodetector (FP) 6, which is connected to the second UT 7. The output of the UT 7 is connected to the second input SU 4. The second part of the optical output stream, passing through the semitransparent mirror 5, irradiates a biological object 8 and is supplied to the second OP 9, the output of which is connected to the input of the third UT 10. The output from UT 10 connected to the input of a differentiating amplifier (DN) 11. To the first output control 11 is connected delay line 12, and the second output - inverted input of the amplifier-discriminator (DD) 13. The output of the delay line 12 is connected respectively with the normal input UD 13. The output UD 13 is connected to the input of the TG 1. It should be noted that within 3, semi-transparent mirror 5, bioobjects 8 and FP 9 are on the same line along the path of the working length of thread between the emitter of the semiconductor laser diode and the second photodetector. Exit within 3 connected to the analog-to-digital Converter (ADC) 14, a first output of which is connected to the Board by the indicator 15. The output of the high-bit ADC 14 is connected to the first input of the first device is a comparison of binary codes (US) 16. To the second input CONDITION 16 is connected to the output of the high-bit programmable permanent memory (EPROM) 17. Accordingly, the output of LSB of the ADC 14 is connected to the first input of the second CONDITION 18. To the second input CONDITION 18 is connected to the output of the low order EPROM 17. The output of the first CONDITION 16 is connected to the input of the first control circuit of the first secondary power source (SU) 19, and the output of the second CONDITION 18 is connected to the input of the second SU 20. As a result, the output of the first SU 19 connected to the input of the first secondary power supply (VIP) 21, the output of which is connected to a second input within 3, and the output of the second SU 20 is connected to the input of the second VIP 22, the output of which is connected with the third input within 3.

The device operates as follows.

When enabled, the device TG 1 produces a rectangular pulse, which is amplified to the level required power first UT 2 and enters the food chain within 3. Created within 3 coherent luminous flux with an arbitrary initial phase of oscillations through the semitransparent mirror 5 is divided into a work, which is used for irradiation of biological object, and stream channel stabilization of the radiation power. Channel stabilization formed the first OP 6 and the second UT 7, which converts the optical signal into an electric, its strengthening and further comparison device 4 with the level of direct signals the first UT 2. The error signal controls the gain of the first UT 2 and stabilizes the power of the radiation flux within 3.

Working luminous flux exposing the biological object 8 that is located in line between within 3 and the second OP 9 in a period of time equal to the duration of the working pulse TG 1. In time, the same length as the front of the working pulse, followed by a response of the biological object at impact, which is expressed in a transition process, since the irradiation is carried out at the resonant frequency of a cancer cell/tissue bio-object. The difference between the initial phases φandand φ0as is known, reflected in the transition of the coupled system, which is fixed to the second OP 9 and the third UT 10. The moment the antiphase signal radiation and of radiation cancer cell may be set as the minimum reverse pulse transition characteristics of the device - biological object. For this purpose, the output signal of the third UT 10 is subjected to differentiation using the remote control 11, the first output of which is connected to the negative input UD 13, and the second output through the delay line 12 normal input UD 13. In fact, the combination of these devices implements the autocorrelation method of reception of pulse signals according to the scheme selection pulse signals according to their duration, which provides processing of the pulse signal is in the background noise. In this arrangement of the processing circuit implements a continuous monitoring of system status device - biological object. An information signal with UD 13 is fed to the input of the TG 1 and controls the starting phase of the operating impulse, moving it in that direction until the output voltage UD 13 reaches its minimum. This is achieved by automatically adjusting/setting the device to the desired mode of relationship between the initial phases of the source light flux and intrinsic vibrations of a cancer cell and its maintenance during the treatment session.

The desired wavelength is within 3, which is a priori, is provided by a special control channel, settings, and automatic maintenance. Constructively within 3 has built-in control system state of the active element, the system of gross and fine adjustment of the working wavelength, which makes it easier to control this device. The condition monitoring system of the active element generates an information signal that enters the ADC 14 and can be decrypted with the display on the scoreboard-the indicator 15. Each instance within 3 passport has a characteristic emission wavelength depending on the information signal embedded control systems. The binary code from the ADC 14 is divided into the elements of the senior and Junior categories. EEPROM 17 stores the binary codes of the resonant frequencies of RA is personal cancerous tissues, to be used in the treatment process. Information codes of the high-order bits of the ADC 14 and the EPROM 17 is compared in the first CONDITION 16 and the signal mismatch error codes entered on the first SU 19. The output signal of the first SU 19 controls the first VIP 21, which with the help of the system coarse adjustment changes the wavelength in the direction until it matches the codes of the high-order bits in the first CONDITION 16. Information codes of the least significant bits of the ADC 14 and the EPROM 17 is compared in the second CONDITION 18 and the signal mismatch error code is delivered to the second SU 20. The output signal of the second SU 20 controls the second VIP 22 which by means of fine adjustment changes the wavelength in the direction until it matches the codes of least significant bits in the second CONDITION 18.

From the above description of the device shows that it consists mainly of standard cell devices, making it publicly available in the installation. The simplicity of the device and automatics maintain it in working position in the presence of interference provides the most extensive of its implementation and use in the implementation of the method of treatment of cancer of various biological systems at any stage.

Sources of information taken into account when drafting

1. Emanuel N.M., R.E. Kavetsky, Tarusov B.N., The OfP H.E. Biophysics of cancer. - Kiev: Nauk. Dumka, 1976. - 296 S.

2. United States Patent 5634922. Jun. 3, 1997. Harada et al. Cancer Diagnosis and Deice Having Laser Beam Generator. Hamamatsu Photonics K.K.

Device for treating cancerous tissue containing a semiconductor laser diode, a translucent mirror for dividing the light flux on the work and the control and display-indicator, wherein the output clock generator connected to the first input of the first DC amplifier, the output of which is connected to the first input of the semiconductor laser diode and the first input of the comparing device, the first photodetector is connected to the input of the second DC amplifier, the output of which is connected to the second input of the comparing device, and its output connected to the second input of the first DC amplifier, a second photodetector connected to the input of the third DC amplifier, the output of which connected to the input of a differentiating amplifier, the first output of the latter is connected with the negative input of the amplifier, discriminator, and the second is connected via a delay line with a normal input of the amplifier discriminator, the output of the amplifier discriminator connected to the input of the clock generator, the output of a semiconductor laser is connected to the input of analog-to-digital Converter, the first output of which is connected to the display/indicator, the second output to the first input of the first comparator binary codes, the third output to the first input of the second comparator, Feb is cnyh codes to the second input of the first comparator binary connected to the first output programmable DC storage device to the second input of the second comparator binary connected to the second output programmable permanent memory device, the output of the first comparator binary connected to the input of the first control circuit secondary power source, the output of which is connected to the input of the first secondary power source, and the output of the second comparator binary connected to the input of the second control circuit secondary power source, the output of which is connected to the input of the second secondary power source, the output of the first secondary power source is connected to a second input of the semiconductor laser diode, and the output second respectively with the third input of the semiconductor laser diode, while the semi-transparent mirror located in the path of the working length of thread between the emitter of the semiconductor laser diode and the second photodetector.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to laser therapy. The first stage of the therapy involves introduction of medicines and intravenous laser blood exposure by installing a needle in one solution transfusion system for quartz fibre of diametre 0.7 mm through which the patient is exposed to helium-neon laser of power 1.2 mW at exposition 90 minutes within seven daily procedures. The second stage includes paravertebral block within herniated disk localisation in projection of herniated disk. Quartz fibre of diametre 0.7 mm is introduced through a puncture needle to the level of surface musculofascial layer. Injection of solution is immediately followed with irradiation with helium-neon laser of power 1.2 mW at exposition 80 minutes within seven daily procedures. Medicines within solution transfusion system are as follows: Trental 5 ml, Actovegin 5 ml, 15% Xantinol Nicotinate 2 ml, vitamin B1 2 ml alternated with vitamin B6 2 ml, 5% vitamin C 3 ml dissolved in physiologic saline 150 ml. Paravertebral block of the first day includes 5% glucocorticoid Diprospan 1 ml combined with 2% Lidocaine. For the following days 2% Lidocaine is used.

EFFECT: method allows terminating inflammatory process, ensuring stable pain management.

3 ex

FIELD: medicine.

SUBSTANCE: therapy of secondary lower limb lymphodema refers to medicine, namely to clinical lymphology. The oatient is exposed to laser light of wavelength 0.6328 mcm combined with intravenous laser irradiation of power 1.2 mW and exposition 90 minutes and intravenous introduction of medicine solutions: Trental, Actovegin, Pheopolyglukine, vitamin B, C complexes, 0.15% xantinol nicotinate. Procedures are daily at seven procedures per course.

EFFECT: therapy provides stable reduction of secondary lower limb lymphodema without therapeutic by-effects, prevents recurrence.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, to neurology. The therapy involves taking the medicines improving cerebral blood circulations. Pharmacotherapy is combined with exposure to laser light within anconeus and popliteal fold regions. Laser puncture covers the points VB 20 and VB 21 symmetrically downright. Laser light is characterised with wavelength 0.89 mcm, power 3 mW and frequency 600 Hz. Herewith light exposure is 1 minute per each point and 2-3 minutes per elbow and popliteal folds. Therapeutic course is 10 days twice every second month.

EFFECT: method reduces treatment time.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, surgery, radiology, physical therapy and can be used for treating patients with larynx cancer. Area of radiation and surrounding tissues is exposed to infrared laser irradiation. From first day of radioreaction diagnostics, exposure to infrared laser irradiation with constant magnetic field with magnetic induction intensity within 20 mTa, recurrence frequency of pulse laser irradiation of infrared spectrum within 80 Hz, power 0.5-1.0 W on all zone of irradiation is performed with defocused ray for 30-120 seconds. Course includes 3-8 procedures with further application on irradiation zones and intake of a teaspoon of cedar nut oil and before going to bed daily during the whole course of radiation therapy.

EFFECT: method allows to increase efficiency of treatment of early radioreactions and prevent development of later radiation damage reducing severity and frequency of their development.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to ophthalmology. Laser stroboscopy is carried out during 5 days, 2 times a day with 1 hour interval. First 10 minutes each eye is influenced in turn, then for 5 minutes both eyes are influenced simultaneously. Distance to speckle is 1 m.

EFFECT: recovering binocular functions with elimination of anisoaccomodation, enhancing binocular interaction, increasing visual acuity.

3 cl, 2 ex

Epilepsy management // 2353411

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at epilepsy management. Carotid and vertebral arteries are sequentially exposed to IR laser light, infra-red laser radiation to the right and to the left each for 5 minutes. Frontal, temporal, parietal and occipital lobes are exposed to magnetic field and microwave radiation to the right and to the left each for 3 minutes. And visual analyser is exposed to IR waves within 30 minutes. It is combined with electroencephalographic training with course of treatment 15 procedures.

EFFECT: disclosed method allows for improved mental measurements, relieved remove proneness to convulsive activity, suppressed epileptogenic zones, improved metabolic and energy cerebral processes, normalised cerebral blood flow regulation, recovered cortical neurodynamic disorders.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology and to be used for neoadjuvant chemoradiotherapy in the patients suffering from thoracic oesophagus cancer. Said therapy is ensured by introduction of cisplatin and leucovorin, and continuous intravenous infusions of fluorouracil dosed 300 mg/m2. Cisplatin solution is introduced intravenously drop-by-drop and dosed 6 mg/m2 daily once a day within 1 hour. Leucovorin is injected intravenously jet-like and dosed 30 mg/m2. Radiotherapy involves daily fractions 3 Gy to total basic dose 30 Gy. The course dose of fluorouracil is 3600 mg/m2, of cisplatin is 72 mg/m2, of leucovorin 360 mg/m2. Chemotherapy and radiotherapy are to be started the same day.

EFFECT: disclosed method allows for considerably reduced toxicity of treatment to be continuous, treatment of the patients originally of bad performance status, for doubly reduced time of neoadjuvant treatment with maintaining high clinical effectiveness.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, urology, physiotherapy and to be used in the patients suffering from chronic pyelonephritis accompanied with chronic prostatitis and chronic cystitis. The method involves taking the mineral water of the Slavjanovsky source dosed 3 - 5 ml per kg of body weight, combined with carbonic mineral baths 35-37°C for 15 minutes 3 times a day, № 8-10, mud "panties" at 40-42°C within 30 minutes to 1.5 hours, prostate massage № 8-10, additionally 50-60 minutes later followed with electropulse therapy combined with exposure to laser magnetic rays. Electropulse therapy involves low-frequency, low-voltage pulse current with a spherical unipolar electrode. Exposure is contact, labile, clockwise and located at skin projection of ascending, transverse and descending large intestine at frequency 30.2 Hz within 8-10 minutes. The course of treatment is 10-12 procedures.

EFFECT: method improves life quality of the patients both in latent phase of inflammatory process, and in mild and moderate active chronic process.

2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns ophthalmology and is intended for treatment of infectious diseases of a cornea. Photodynamic therapy with the use of gel containing an octacation phthalocyanine of zinc in concentration of 1-3 mg/ml, which is applied on a cornea as a photosensitinogen, is performed. The conjunctival cavity is washed out after 30 - 40 minutes and influenced with a laser radiation with a wavelength of 675 nm with a light dose 20 - 60 J/cm2 in of 5 minutes, once a day. 1-8 sessions during each course.

EFFECT: method allows destroying the originator of keratitis in a cell with the maximum safety of surrounding tissues of the cornea.

2 tbl, 3 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely, physiotherapy, reflexotherapy. Prior to the beginning of backbone extension acupuncture by the rule "Mother-son" is performed. In 3-5 days the backbone is simultaneously influenced with a magnetic-laser radiation and extension is performed. The magnetic-laser radiation influence is spent in red 630-650 nm and infra-red 890-950 nm ranges with 50 mT intensity of a magnetic field. Backbone extension is spent in mass of a load by 15-30 kg. Total time of the procedure makes 15-20 minutes.

EFFECT: method increases analgetic effect, reduces puffiness and improves microcirculation and trophicity of tissues.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns virology. Method involves use of visible spectral range with application of water-soluble photo sensitivisers of cationic type, added to virus-containing medium in 0.25-2 kg/ml concentration before irradiation. Method is characterised by low photo sensitiviser concentrations and safe white or red light, providing for method effectiveness and safety. Invention can be applied in photo decontamination of bird influenza A virus of H5N1 subtype ('bird flu' virus) for various media.

EFFECT: additionally, shrinkage of ever expanding prevalence of diseases caused by 'bird flu' virus.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to laser therapy. The first stage of the therapy involves introduction of medicines and intravenous laser blood exposure by installing a needle in one solution transfusion system for quartz fibre of diametre 0.7 mm through which the patient is exposed to helium-neon laser of power 1.2 mW at exposition 90 minutes within seven daily procedures. The second stage includes paravertebral block within herniated disk localisation in projection of herniated disk. Quartz fibre of diametre 0.7 mm is introduced through a puncture needle to the level of surface musculofascial layer. Injection of solution is immediately followed with irradiation with helium-neon laser of power 1.2 mW at exposition 80 minutes within seven daily procedures. Medicines within solution transfusion system are as follows: Trental 5 ml, Actovegin 5 ml, 15% Xantinol Nicotinate 2 ml, vitamin B1 2 ml alternated with vitamin B6 2 ml, 5% vitamin C 3 ml dissolved in physiologic saline 150 ml. Paravertebral block of the first day includes 5% glucocorticoid Diprospan 1 ml combined with 2% Lidocaine. For the following days 2% Lidocaine is used.

EFFECT: method allows terminating inflammatory process, ensuring stable pain management.

3 ex

FIELD: medicine.

SUBSTANCE: therapy of secondary lower limb lymphodema refers to medicine, namely to clinical lymphology. The oatient is exposed to laser light of wavelength 0.6328 mcm combined with intravenous laser irradiation of power 1.2 mW and exposition 90 minutes and intravenous introduction of medicine solutions: Trental, Actovegin, Pheopolyglukine, vitamin B, C complexes, 0.15% xantinol nicotinate. Procedures are daily at seven procedures per course.

EFFECT: therapy provides stable reduction of secondary lower limb lymphodema without therapeutic by-effects, prevents recurrence.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, to neurology. The therapy involves taking the medicines improving cerebral blood circulations. Pharmacotherapy is combined with exposure to laser light within anconeus and popliteal fold regions. Laser puncture covers the points VB 20 and VB 21 symmetrically downright. Laser light is characterised with wavelength 0.89 mcm, power 3 mW and frequency 600 Hz. Herewith light exposure is 1 minute per each point and 2-3 minutes per elbow and popliteal folds. Therapeutic course is 10 days twice every second month.

EFFECT: method reduces treatment time.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: there is prescribed gluten-free diet with eliminating cereals and additional order of protein: meat 100.0 g, cottage cheese 100.0 g, or sour cream 100.0 g daily. Creon is dosed 10000 ME at mealtime within 2 weeks. It is combined with physiotherapy exercises (PTE) within 20-30 minutes. During afternoon, every second day circular douche is applied at pressure 1.5-2 atmospheres, water temperature 36-35°C for 3-4 minutes within therapeutic course 10-12 procedures. On another days, radon baths are taken at water temperature 36°C, dosed 0.75 kBq/l for 8-10 minutes within therapeutic course 8-10 procedures. Electrophoresis is applied daily with 50% Dimexide solution (±) for small intestine projection by transverse technique, current density 0.05 mA/cm2 within 12-15 minutes within therapeutic course 10-12. The BAPs VC-20, VC-22, E-36, Gi-4 are exposed to red and infrared light daily within 1.5-2 minutes per each point within therapeutic course 10-12 procedures.

EFFECT: reduced specific immunologic markers of autoimmune intestine inflammations and cytokine generation level, normalised immune response of an organism, normalised hormonal and exchange processes.

2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, surgery, radiology, physical therapy and can be used for treating patients with larynx cancer. Area of radiation and surrounding tissues is exposed to infrared laser irradiation. From first day of radioreaction diagnostics, exposure to infrared laser irradiation with constant magnetic field with magnetic induction intensity within 20 mTa, recurrence frequency of pulse laser irradiation of infrared spectrum within 80 Hz, power 0.5-1.0 W on all zone of irradiation is performed with defocused ray for 30-120 seconds. Course includes 3-8 procedures with further application on irradiation zones and intake of a teaspoon of cedar nut oil and before going to bed daily during the whole course of radiation therapy.

EFFECT: method allows to increase efficiency of treatment of early radioreactions and prevent development of later radiation damage reducing severity and frequency of their development.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to ophthalmology. Laser stroboscopy is carried out during 5 days, 2 times a day with 1 hour interval. First 10 minutes each eye is influenced in turn, then for 5 minutes both eyes are influenced simultaneously. Distance to speckle is 1 m.

EFFECT: recovering binocular functions with elimination of anisoaccomodation, enhancing binocular interaction, increasing visual acuity.

3 cl, 2 ex

Epilepsy management // 2353411

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at epilepsy management. Carotid and vertebral arteries are sequentially exposed to IR laser light, infra-red laser radiation to the right and to the left each for 5 minutes. Frontal, temporal, parietal and occipital lobes are exposed to magnetic field and microwave radiation to the right and to the left each for 3 minutes. And visual analyser is exposed to IR waves within 30 minutes. It is combined with electroencephalographic training with course of treatment 15 procedures.

EFFECT: disclosed method allows for improved mental measurements, relieved remove proneness to convulsive activity, suppressed epileptogenic zones, improved metabolic and energy cerebral processes, normalised cerebral blood flow regulation, recovered cortical neurodynamic disorders.

1 ex

Epilepsy management // 2353411

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at epilepsy management. Carotid and vertebral arteries are sequentially exposed to IR laser light, infra-red laser radiation to the right and to the left each for 5 minutes. Frontal, temporal, parietal and occipital lobes are exposed to magnetic field and microwave radiation to the right and to the left each for 3 minutes. And visual analyser is exposed to IR waves within 30 minutes. It is combined with electroencephalographic training with course of treatment 15 procedures.

EFFECT: disclosed method allows for improved mental measurements, relieved remove proneness to convulsive activity, suppressed epileptogenic zones, improved metabolic and energy cerebral processes, normalised cerebral blood flow regulation, recovered cortical neurodynamic disorders.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology and to be used for neoadjuvant chemoradiotherapy in the patients suffering from thoracic oesophagus cancer. Said therapy is ensured by introduction of cisplatin and leucovorin, and continuous intravenous infusions of fluorouracil dosed 300 mg/m2. Cisplatin solution is introduced intravenously drop-by-drop and dosed 6 mg/m2 daily once a day within 1 hour. Leucovorin is injected intravenously jet-like and dosed 30 mg/m2. Radiotherapy involves daily fractions 3 Gy to total basic dose 30 Gy. The course dose of fluorouracil is 3600 mg/m2, of cisplatin is 72 mg/m2, of leucovorin 360 mg/m2. Chemotherapy and radiotherapy are to be started the same day.

EFFECT: disclosed method allows for considerably reduced toxicity of treatment to be continuous, treatment of the patients originally of bad performance status, for doubly reduced time of neoadjuvant treatment with maintaining high clinical effectiveness.

2 ex

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

Up!